Bacteriophage Therapy of Bacterial Infections: An Update of our Institute’s Experience

Weber‐Dąbrowska, Beata; Mulczyk, M; Górski, Andrzej

doi:10.1007/978-94-015-9702-9_15

Cited by 121 publications

(137 citation statements)

References 11 publications

Supporting

Mentioning

132

Contrasting

Unclassified

Order By: Relevance

“…Of the 31 cases, 77% showed improvements in condition [70]. Later, the same group reported a broader study with a larger number of patients and obtained similar results [71]. [76].…”

Section: Recent Research In the Use Of Phages As Antimicrobialmentioning

confidence: 77%

Bacteriophages and Their Derivatives as Biotherapeutic Agents in Disease Prevention and Treatment

et al. 2014

View full text Add to dashboard Cite

The application of bacteriophages for the elimination of pathogenic bacteria has received significantly increased attention worldwide in the past decade. This is borne out by the increasing prevalence of bacteriophage-specific conferences highlighting significant and diverse advances in the exploitation of bacteriophages. While bacteriophage therapy has been associated with the Former Soviet Union historically, since the 1990s, it has been widely and enthusiastically adopted as a research topic in Western countries. This has been justified by the increasing prevalence of antibiotic resistance in many prominent human pathogenic bacteria. Discussion of the therapeutic aspects of bacteriophages in this review will include the uses of whole phages as antibacterials and will also describe studies on the applications of purified phage-derived peptidoglycan hydrolases, which do not have the constraint of limited bacterial host-range often observed with whole phages.

show abstract

“…Of the 31 cases, 77% showed improvements in condition [70]. Later, the same group reported a broader study with a larger number of patients and obtained similar results [71]. [76].…”

Section: Recent Research In the Use Of Phages As Antimicrobialmentioning

confidence: 77%

Bacteriophages and Their Derivatives as Biotherapeutic Agents in Disease Prevention and Treatment

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Phages continue to be used in place of antibiotics for the treatment of bacterial infections in the former Soviet Union and Eastern Europe (1,15,32,42). The ongoing active bacterial evolution of multidrug resistance has recently motivated the Western scientific community to reevaluate the therapeutic potential of phages for diverse bacterial infections that are often incurable with conventional chemotherapy (1,15,25,40).…”

Section: Fatality Rates Among Patients With Infections Caused Bymentioning

confidence: 99%

Efficacy of Bacteriophage Therapy against Gut-Derived Sepsis Caused by Pseudomonas aeruginosa in Mice

Watanabe

Matsumoto

Sano

et al. 2007

Antimicrob Agents Chemother

192

130

View full text Add to dashboard Cite

We evaluated the efficacy of bacteriophage (phage) therapy by using a murine model of gut-derived sepsis caused by Pseudomonas aeruginosa that closely resembles the clinical pathophysiology of septicemia in humans. Oral administration of a newly isolated lytic phage strain (KPP10) significantly protected mice against mortality (survival rates, 66.7% for the phage-treated group versus 0% for the saline-treated control group; P < 0.01). Mice treated with phage also had lower numbers of viable P. aeruginosa cells in their blood, liver, and spleen. The levels of inflammatory cytokines (tumor necrosis factor alpha TNF-␣, interleukin-1␤ [IL-1␤], and IL-6) in blood and liver were significantly lower in phage-treated mice than in phage-untreated mice. The number of viable P. aeruginosa cells in fecal matter in the gastrointestinal tract was significantly lower in phage-treated mice than in the saline-treated control mice. We also studied the efficacy of phage treatment for intraperitoneal infection caused by P. aeruginosa and found that phage treatment significantly improved the survival of mice, but only under limited experimental conditions. In conclusion, our findings suggest that oral administration of phage may be effective against gut-derived sepsis caused by P. aeruginosa.

show abstract

“…Oral, subcutaneous or topical phage therapy were often used in children infections for treatment of osteomyelitis, myositis, suppurative wounds, respiratory infections, skin and subcutaneous tissues infections, furunculosis, gastrointestinal infections, and even in septicemia (12,14,73,74).…”

Section: What Challenges Do We Face For Treatments With Endolysin?mentioning

confidence: 99%

Endolysins of Bacteriophages as an Anti-Methicillin Resistant Staphylococcus aureus Infection in Children: A Narrative Review

Rahimzadeh¹,

Gill²,

Rezai³

2017

J Pediatr Rev

View full text Add to dashboard Cite

Context: Spread of Methicillin-resistant Staphylococcus aureus (MRSA) can cause serious and sometimes fatal diseases especially in children. Outbreaks and increasing the prevalence of antibiotic-resistant MRSA at pediatric hospital calls for the development of novel preservation techniques. Endolysins and bacteriophages have been used successfully to control bacterial infections in children. Endolysins were considered as a useful treatment especially for the pathogens without disturbing the normal flora, the low chance of bacterial resistance, and their ability to kill colonizing pathogens on mucosal surfaces. Herein, we aimed to review the effectiveness of endolysins of bacteriophage for controlling methicillin-resistant Staphylococcus aureus infections in children.Evidence Acquisition: This review was performed by searching studies indexed in international databases including PubMed, Scopus, Web of Science, Science Direct, as well as Google Scholar published from 2000 until 2016.Results: Experimental data show that endolysins of Staphylococcus aureus bacteriophage can be used to combat methicillinresistant Staphylococcus aureus infections in children. Conclusions:Endolysins of bacteriophages could be effective for controlling a variety of methicillin-resistant Staphylococcus aureus infections.

show abstract

Bacteriophage Therapy of Bacterial Infections: An Update of our Institute’s Experience

Cited by 121 publications

References 11 publications

Bacteriophages and Their Derivatives as Biotherapeutic Agents in Disease Prevention and Treatment

Bacteriophages and Their Derivatives as Biotherapeutic Agents in Disease Prevention and Treatment

Efficacy of Bacteriophage Therapy against Gut-Derived Sepsis Caused by Pseudomonas aeruginosa in Mice

Endolysins of Bacteriophages as an Anti-Methicillin Resistant Staphylococcus aureus Infection in Children: A Narrative Review

Contact Info

Product

Resources

About